$TARA News

Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD Cowen

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations - Slideshow

Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

Protara Therapeutics To Host Investor Webinar On TARA-002 Program And Treatment Landscape For Lymphatic Malformations On May 19, 2026

Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

Protara Therapeutics Reports TARA-002 Achieves 72% Complete Response Rate In BCG-Naïve NMIBC Patients With Durable 55% Rate At 12 Months

JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26

Protara Therapeutics Q1 EPS $(0.31) Beats $(0.37) Estimate

HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Raises Price Target to $27

Protara Therapeutics To Demonstrate Interim Data From Cohort A Of Its Current Phase 2 Open-Label ADVANCED-2 Study Of TARA-002 In Participants With BCG-Naïve Non-Muscle Invasive Bladder Cancer At American Urological Association 2026 Annual Meeting

Protara Therapeutics: Q4 Earnings Snapshot

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Protara Therapeutics Q4 EPS $(0.37) Misses $(0.33) Estimate

JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27

Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf

Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers Symposium - Slideshow

Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU

Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - Slideshow

Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript